NASDAQ : SION
Sionna Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 3.78 USD (Oct 30, 2026, 2:41 PM EDT) · Market cap 170.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 37.45M | 28.72M | 13.27M | 9.71M | 6.77M |
| Research & Development | 72.04M | 60.26M | 57.29M | 40.63M | 34.60M |
| Operating Expenses | 109.49M | 88.98M | 70.56M | 50.33M | 41.37M |
| Operating Income | -109.49M | -88.98M | -70.56M | -50.33M | -41.37M |
| Interest & Investment Income | 12.04M | 13.29M | 8.17M | 2.77M | 1.13M |
| Other Non Operating Income (Expenses) | 68.00K | 419.00K | 698.00K | 301.00K | |
| Pretax Income | -97.38M | -75.27M | -61.69M | -47.26M | -40.24M |
| Net Income | -97.38M | -75.27M | -61.69M | -47.26M | -40.24M |
| Net Income to Common | -97.38M | -75.27M | -61.69M | -47.26M | -40.24M |
| Shares Outstanding (Basic) | 44.91M | 39.96M | 3.86M | 2.93M | 2.58M |
| Shares Outstanding (Diluted) | 44.91M | 39.96M | 3.86M | 2.93M | 2.58M |
| EPS (Basic) | -2.17 | -1.88 | -15.99 | -16.11 | -15.61 |
| EPS (Diluted) | -2.17 | -1.88 | -15.99 | -16.11 | -15.61 |
| Free Cash Flow | -76.21M | -66.67M | -52.81M | -44.81M | -37.94M |
| Free Cash Flow Per Share | -1.70 | -1.67 | -13.69 | -15.28 | -14.72 |
| EBITDA | -108.84M | -88.33M | -69.89M | -49.75M | -41.25M |
| D&A For EBITDA | 650.00K | 647.00K | 668.00K | 583.00K | 122.00K |
| EBIT | -109.49M | -88.98M | -70.56M | -50.33M | -41.37M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.32M | 58.45M | 37.79M | 38.52M | 54.84M |
| Short-Term Investments | 147.71M | 177.43M | 109.75M | 27.77M | |
| Cash & Short-Term Investments | 211.03M | 235.88M | 147.54M | 38.52M | 82.61M |
| Prepaid Expenses | 5.10M | 5.54M | 3.46M | 686.00K | 1.22M |
| Total Current Assets | 216.13M | 241.42M | 150.99M | 39.21M | 83.83M |
| Property, Plant & Equipment | 8.34M | 9.15M | 10.30M | 11.62M | 1.79M |
| Long-Term Investments | 57.22M | 74.42M | 20.50M | ||
| Other Long-Term Assets | 1.56M | 963.00K | 3.96M | 1.12M | 1.74M |
| Total Assets | 283.25M | 325.95M | 185.75M | 51.95M | 87.37M |
| Accounts Payable | 523.00K | 769.00K | 1.19M | 719.00K | 557.00K |
| Accrued Expenses | 8.88M | 9.67M | 7.67M | 6.59M | 7.70M |
| Current Portion of Leases | 1.38M | 1.27M | 1.07M | 728.00K | |
| Other Current Liabilities | 7.00K | 6.00K | 492.00K | ||
| Total Current Liabilities | 10.78M | 11.71M | 10.42M | 8.04M | 8.25M |
| Long-Term Leases | 6.69M | 7.41M | 8.68M | 9.75M | |
| Total Liabilities | 17.47M | 19.12M | 19.10M | 17.79M | 8.25M |
| Common Stock | 45.00K | 45.00K | 5.00K | 2.00K | 2.00K |
| Additional Paid-In Capital | 579.20M | 562.60M | 17.00M | 4.51M | 2.23M |
| Retained Earnings | -313.02M | -256.35M | -181.09M | -119.40M | -72.14M |
| Comprehensive Income & Other | -448.00K | 540.00K | 368.00K | -16.00K | |
| Total Common Equity | 265.77M | 306.83M | -163.71M | -114.88M | -69.92M |
| Shareholders' Equity | 265.77M | 306.83M | 166.66M | 34.16M | 79.12M |
| Total Liabilities & Equity | 283.25M | 325.95M | 185.75M | 51.95M | 87.37M |
| Total Debt | 8.07M | 8.68M | 9.75M | 10.48M | |
| Net Cash (Debt) | 260.18M | 301.62M | 158.29M | 28.04M | 82.61M |
| Net Cash Per Share | 5.79 | 7.55 | 41.02 | 9.56 | 32.05 |
| Filing Date Shares Outstanding | 45.21M | 45.00M | 44.12M | 3.05M | 2.58M |
| Total Common Shares Outstanding | 45.16M | 44.72M | 4.72M | 3.05M | 2.58M |
| Working Capital | 205.35M | 229.71M | 140.57M | 31.17M | 75.58M |
| Book Value Per Share | 5.88 | 6.86 | -34.66 | -37.66 | -27.13 |
| Tangible Book Value | 265.77M | 306.83M | -163.71M | -114.88M | -69.92M |
| Tangible Book Value Per Share | 5.88 | 6.86 | -34.66 | -37.66 | -27.13 |
| Machinery | 2.43M | 2.43M | 2.18M | 2.05M | 617.00K |
| Construction In Progress | 1.52M | ||||
| Leasehold Improvements | 1.92M | 1.92M | 1.85M | 1.85M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -97.38M | -75.27M | -61.69M | -47.26M | -40.24M |
| Depreciation & Amortization | 650.00K | 647.00K | 668.00K | 583.00K | 122.00K |
| Loss (Gain) From Sale of Investments | -1.55M | -3.05M | -3.00M | -679.00K | -400.00K |
| Stock-Based Compensation | 20.53M | 12.07M | 3.71M | 2.26M | 1.69M |
| Other Operating Activities | 1.96M | 1.96M | 10.60M | 2.18M | |
| Change in Accounts Payable | -468.00K | -417.00K | 467.00K | 162.00K | -1.51M |
| Change in Other Net Operating Assets | 342.00K | -2.23M | -3.54M | -945.00K | 4.28M |
| Operating Cash Flow | -75.92M | -66.30M | -52.79M | -43.70M | -36.07M |
| Capital Expenditures | -291.00K | -377.00K | -27.00K | -1.12M | -1.87M |
| Investment in Securities | 92.27M | -118.37M | -126.89M | 28.47M | -27.39M |
| Investing Cash Flow | 91.98M | -118.75M | -126.91M | 27.35M | -29.26M |
| Issuance of Common Stock | 6.83M | 205.71M | 141.00K | 31.00K | 64.00K |
| Other Financing Activities | -550.00K | -2.50M | -200.00K | ||
| Financing Cash Flow | 6.28M | 205.71M | 178.97M | 31.00K | 110.86M |
| Net Cash Flow | 22.34M | 20.66M | -733.00K | -16.32M | 45.52M |
| Free Cash Flow | -76.21M | -66.67M | -52.81M | -44.81M | -37.94M |
| Free Cash Flow Per Share | -1.70 | -1.67 | -13.69 | -15.28 | -14.72 |
| Levered Free Cash Flow | -45.44M | -44.26M | -40.48M | -30.14M | |
| Unlevered Free Cash Flow | -45.44M | -44.26M | -40.48M | -30.14M | |
| Change in Working Capital | -126.00K | -2.65M | -3.08M | -783.00K | 2.76M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 174.97M | 1.84B | |||
| Enterprise Value | -85.21M | 1.52B | |||
| Last Close Price | 3.87 | 41.14 | |||
| PB Ratio | 0.66 | 5.98 | |||
| P/TBV Ratio | 0.66 | 5.98 | |||
| Debt / Equity Ratio | 0.03 | 0.03 | 0.06 | 0.31 | |
| Net Debt / Equity Ratio | -0.98 | -0.98 | -0.95 | -0.82 | -1.04 |
| Net Debt / EBITDA Ratio | 2.39 | 3.42 | 2.27 | 0.56 | 2.00 |
| Net Debt / FCF Ratio | 3.41 | 4.52 | 3.00 | 0.63 | 2.18 |
| Quick Ratio | 19.57 | 20.14 | 14.16 | 4.79 | 10.01 |
| Current Ratio | 20.05 | 20.61 | 14.49 | 4.88 | 10.16 |
| Return on Equity (ROE) | -32.34% | -31.79% | -61.44% | -83.45% | |
| Return on Assets (ROA) | -21.54% | -21.74% | -37.10% | -45.16% | |
| Return on Capital Employed (ROCE) | -40.20% | -28.30% | -40.20% | -114.60% | -52.30% |
| Earnings Yield | -56.03% | -4.10% | |||
| FCF Yield | -43.55% | -3.63% | |||
| Buyback Yield / Dilution | -124.56% | -935.60% | -31.56% | -13.80% |